Original estimates of breast and ovarian cancer risks in carriers were based on the families used for positional cloning of the BRCA1 and BRCA2 genes, where all carriers had molecular testing, and all cancer diagnoses were validated. This evidence concerns the gene BRCA1 and cancer.